CicloMulsion Trial Failure Leaves NeuroVive Dependent On NeuroSTAT

NeuroVive of Sweden pulled the plug on its lead cyclophilin inhibitor after it showed no benefit in preventing acute kidney injury in patients treated with the therapy prior to open heart surgery – but the specialty pharma says it has other early assets to concentrate on now.